First elected: 4th July 2024
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
These initiatives were driven by Peter Fortune, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Peter Fortune has not been granted any Urgent Questions
Peter Fortune has not been granted any Adjournment Debates
Peter Fortune has not introduced any legislation before Parliament
Peter Fortune has not co-sponsored any Bills in the current parliamentary sitting
The CMA has been given bespoke tools to increase competition in digital markets through the Digital Markets, Competition, Consumers Act 2024. Strategic Market Status investigations are the gateway into the regime and interested stakeholders can engage with the process, including firms under investigation, relevant third parties and the wider public.
Decisions on which SMS investigations to start are for the CMA as the UK’s independent competition authority.
The Competition and Markets Authority (CMA) is the UK's independent competition authority, and its consultations, including the live consultation relating to commitments offered by Vifor Pharma (https://www.gov.uk/government/consultations/consultation-on-proposed-commitments-in-respect-of-vifor-pharmas-supply-of-intravenous-iron), are therefore independent of Government. Any questions relating to consultations carried out by the CMA should be sent directly to the CMA.
The consultation on the implementation of the subscription contracts follows the UK Government Consultation principles (Consultation principles: guidance - GOV.UK).
The subscription consultation is available in HTML and PDF formats. HTML provides greater accessibility for users. The PDF was published as an accessible PDF.
Alternative methods of completing the consultation are available including online, via email and via post.
The Department launched the call for evidence ‘Developing an energy smart data scheme’ on 13 January 2025, with more information available at the following link:
https://www.gov.uk/government/calls-for-evidence/developing-an-energy-smart-data-scheme (opens in a new tab)
As per the Department's accessible documents policy, the call for evidence document is published on GOV.UK and provided as both a tagged PDF and HTML so screen readers can understand the page structure. The digital survey for users to respond to the call for evidence is also hosted on an accessible platform.
Users of assistive technology (such as screen readers) can request a copy of the call for evidence in an accessible format by emailing alt.formats@energysecurity.gov.uk. Users who have queries on the call for evidence can also contact digitalisation@energysecurity.gov.uk.
The Department launched the consultation ‘Funding mechanism for the Hydrogen Production Business Model: proposed design of the Gas Shipper Obligation’ on 16 January 2025, with more information available at the following link:
https://www.gov.uk/government/consultations/funding-mechanism-for-the-hydrogen-production-business-model-proposed-design-of-the-gas-shipper-obligation
(opens in a new tab)
As per the Department's accessible documents policy guidance, the consultation document is published on GOV.UK and provided as both a tagged PDF and HTML so screen readers can understand the page structure. The digital survey for users to respond to the consultation is also hosted on an accessible platform.
Users of assistive technology (such as screen readers) can request a copy of the consultation in an accessible format by emailing alt.formats@energysecurity.gov.uk. Users who have queries on the consultation can also contact GasShipperObligation@energysecurity.gov.uk.
The UK ETS Authority published the Free Allocation Review Carbon Leakage consultation in response to a call from stakeholders to see a draft UK Carbon Leakage List. The consultation also seeks to provides greater clarity on Free Allocation adjustments for sectors covered by the UK Carbon Border Adjustment Mechanism. While the consultation is technical in nature, there are annexes published alongside it to explain the methodology taken to develop proposals. In addition, during the consultation window over January to March, events for UK ETS participants and other interested stakeholders will take place to improve accessibility of the technical content.
The Department launched the consultation ‘Raising product standards for space heating’ on GOV.UK on 17 December 2024, with more information available at the following link:
https://www.gov.uk/government/consultations/raising-product-standards-for-space-heating (opens in a new tab)
Users of assistive technology (such as screen readers) can request a copy of the consultation and supporting documents in an accessible format by emailing alt.formats@energysecurity.gov.uk. Users who have queries on the consultation can also contact spaceheatingstandards@energysecurity.gov.uk.
The Department published the consultation on Capacity Market: proposals to modernise Rules and improve participation and delivery assurance of consumer-led flexibility on GOV.UK and is content that it meets the expected accessibility standards to allow all interested parties to contribute their views.
Users of assistive technology (such as screen readers) can request a copy of the consultation in an alternative format by emailing alt.formats@energysecurity.gov.uk.
Accessible versions of the Energy Company Obligation (ECO4) and Great British Insulation Scheme (GBIS) mid-scheme changes consultation (and all related documents) can be made available upon request at: https://www.gov.uk/government/consultations/energy-company-obligation-4-and-the-great-british-insulation-scheme-mid-scheme-changes
Requestors are asked to submit a form to the relevant team to ensure accessibility requests are reasonable and proportionate.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus
Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.
MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
The Action Plan has been informed by a series of external roundtables with experts from across the AI ecosystem. These discussions covered key areas such as the collaboration between the public and private sectors to create a robust AI ecosystem and to unmask the potential economic impact of AI technologies. As the Government takes the Plan forward, it will continue to engage widely with these stakeholders to ensure its implementation.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
The Action Plan was informed by a series of external roundtables with experts from across the AI ecosystem including civil society, academia, investors, and industry, including from UKRI. The department also regularly engages with the Horizon Programme and the responsible EU officials. These discussions have informed the action plan and continue to shape our ongoing work.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
The Secretary of State for Science, Innovation and Technology engaged in numerous discussions with various stakeholders and government departments as part of the broader effort to ensure the AI Opportunities Action Plan was comprehensive and aligned with the government’s ambition for growth. The Geospatial Commission is part of the Department for Science, Innovation and Technology. Officials in geospatial and AI policy engage regularly, including on the AI Action Plan.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.
The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.
UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.